Evidence map›Paper›PMID 23884863›Full record

ArticleJournal of psychopharmacology (Oxford, England)2013

The size, burden and cost of disorders of the brain in the UK.

Naomi A Fineberg, Peter M Haddad, Lewis Carpenter, Brenda Gannon, Rachel Sharpe, Allan H Young, Eileen Joyce, James Rowe, David Wellsted, David J Nutt and 1 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychopharmacology (Oxford, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01680237 (Cognitive Behavior Therapy vs Exposure in Vivo in the Treatment of Panic Disorder With Agoraphobia), which is not on this map. Cited by 87 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 12 pooled it
8.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01680237 naterminatednot on this map

Cognitive Behavior Therapy vs Exposure in Vivo in the Treatment of Panic Disorder With Agoraphobia

TypeinterventionalSponsorRuhr University of BochumRan2011 to 2023Enrolled130ConditionsPanic Disorder With AgoraphobiaArmsCognitive behavior therapy, Exposure in-vivo
3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 12 syntheses or guidelines pooled it, 216 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Naomi A FinebergHertfordshire Partnership NHS University Foundation Trust, Queen Elizabeth II Hospital, Welwyn Garden City, UK. kiri_researchhpft@yahoo.com
Peter M Haddad
Lewis Carpenter
Brenda Gannon
Rachel Sharpe
Allan H Young
Eileen Joyce
James Rowe
David Wellsted
David J Nutt
Barbara J Sahakian
Addenbrooke's Hospital · GBUniversity of Hertfordshire · GBImperial College London · GBUniversity College London · GBUniversity of Leeds · GBUniversity of Manchester · GB

Funding

Department of Health PB-PG-0110-21073Department of Health PB-PG-0909-19044Medical Research Council G0001354Medical Research Council G1002226Medical Research Council MC_U105597119Wellcome Trust 088324Wellcome Trust 089589/Z/09/Z
6 · The paper itself

Abstract

aimThe aim of this paper is to increase awareness of the prevalence and cost of psychiatric and neurological disorders (brain disorders) in the UK.

methodUK data for 18 brain disorders were extracted from a systematic review of European epidemiological data and prevalence rates and the costs of each disorder were summarized (2010 values).

resultsThere were approximately 45 million cases of brain disorders in the UK, with a cost of €134 billion per annum. The most prevalent were headache, anxiety disorders, sleep disorders, mood disorders and somatoform disorders. However, the five most costly disorders (€ million) were: dementia: €22,164; psychotic disorders: €16,717; mood disorders: €19,238; addiction: €11,719; anxiety disorders: €11,687. Apart from psychosis, these five disorders ranked amongst those with the lowest direct medical expenditure per subject (<€3000). The approximate breakdown of costs was: 50% indirect costs, 25% direct non-medical and 25% direct healthcare costs. DISCUSSION: The prevalence and cost of UK brain disorders is likely to increase given the ageing population. Translational neurosciences research has the potential to develop more effective treatments but is underfunded. Addressing the clinical and economic challenges posed by brain disorders requires a coordinated effort at an EU and national level to transform the current scientific, healthcare and educational agenda.

Indexed as

AdolescentAdultAgedAged, 80 and overBrainBrain DiseasesChildChild, PreschoolCost of IllnessDelivery of Health CareHealth Care CostsHumansMental DisordersMiddle AgedPrevalenceUnited KingdomBrain disordersburdencost

Identifiers

PMID23884863
PMCPMC3778981
OpenAlexW2130780062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.